Defining Progression in Metastatic Kidney Cancer
3 Tampilan
• 06/26/23
0
0
Menanamkan
administrator
Pelanggan
Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.
Menampilkan lebih banyak
Komentar Facebook
SORT BY-
Komentar Teratas
-
komentar terbaru